There are ~23,500 genes in every human cell. While this would appear to be a large number, it is estimated that over 500,000 proteins are present within the cell at any one moment, and furthermore, 80% of these reside in protein heterocomplexes. Many proteins are altered by post-translational modifications that impact subcellullar location, protein activity, protein binding partners and organellar trafficking. All of this complexity impacts gene expression and cell function. Importantly, many protein interactions arise from cell-to-cell- mediated signaling in a tissue-restricted manner and we now understand that protein-protein interactions, signal transduction and gene expression are context-specific. For example, the functional consequences of a given gene expressed during development can be quite different when the same gene is expressed in the adult, as seen with embryonic genes that are re-expressed in cancer cells (1). Indeed, it can be stated with confidence that cell autonomous genetic changes within an incipient cancer cell in collaboration with alterations in the microenvironment contribute to neoplastic progression. The importance of microenvironment and context in neoplastic progression is well accepted (2). Thus, there is increasing need for studies of the genetic and molecular basis of cancer to migrate to the whole organism to correctly capture relevant molecular mechanisms in the proper context. This underlies the rationale for molecular imaging as envisioned by the Washington University In Vivo Cellular and Molecular Imaging Center (WU ICMIC). In particular, integration of genetically encoded imaging reporters into live cells and small animal models of cancer has provided powerful tools to monitor cancer-associated molecular, biochemical, and cellular pathways in vivo (3-6). New animal models combined with imaging techniques (nuclear, MR, fluorescence and bioluminescence) at both macroscopic and microscopic scales will make it possible to explore the consequences of the interactions between tumor cells and microenvironment in vivo in real-time. Ground-breaking studies have demonstrated that molecular imaging is a powerful tool that enables visualization of gene expression, biochemical reactions, signal transduction and regulatory pathways in whole organisms in vivo. Novel injectable agents under development that target key activities may someday enable investigators and clinicians to visualize these processes in patients. With the development of suitable probes and instrumentation for functional imaging in vivo, our ability to identify and measure biological processes in real-time has progressively extended to the whole organism, from mice to humans.

Public Health Relevance

The objective of the WU ICMIC is to combine the institutional expertise of Washington University in the basic sciences of molecular oncology and signal transduction with our well developed infrastructure in medical imaging for the advancement of oncotogic molecular imaging projects. The P50 Program promotes excellence in molecular imaging by providing a regional/national conduit for interdisciplinary collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA094056-14
Application #
8658378
Study Section
Special Emphasis Panel (ZCA1-SRLB-9)
Project Start
2014-01-01
Project End
2016-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
14
Fiscal Year
2014
Total Cost
$231,484
Indirect Cost
$171,095
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Pisaneschi, Federica; Kelderhouse, Lindsay E; Hardy, Amanda et al. (2017) Automated, Resin-Based Method to Enhance the Specific Activity of Fluorine-18 Clicked PET Radiotracers. Bioconjug Chem 28:583-589
Zhu, Zhe; Gorman, Matthew J; McKenzie, Lisa D et al. (2017) Zika virus has oncolytic activity against glioblastoma stem cells. J Exp Med 214:2843-2857
Zhang, Daoxiang; Li, Lin; Jiang, Hongmei et al. (2017) Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 23:1748-1759
Lu, Zhi Hong; Kaliberov, Sergey; Sohn, Rebecca E et al. (2017) A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector. Oncotarget 8:12272-12289
Miller, Jessica; Wang, Steven T; Orukari, Inema et al. (2017) Perfusion-based fluorescence imaging method delineates diverse organs and identifies multifocal tumors using generic near-infrared molecular probes. J Biophotonics :
Miller, Jessica P; Habimana-Griffin, LeMoyne; Edwards, Tracy S et al. (2017) Multimodal fluorescence molecular imaging for in vivo characterization of skin cancer using endogenous and exogenous fluorophores. J Biomed Opt 22:66007
Zacharias, Niki Marie; McCullough, Christopher; Shanmugavelandy, Sriram et al. (2017) Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer. Sci Rep 7:16159
Gilson, Rebecca C; Black, Kvar C L; Lane, Daniel D et al. (2017) Hybrid TiO2 -Ruthenium Nano-photosensitizer Synergistically Produces Reactive Oxygen Species in both Hypoxic and Normoxic Conditions. Angew Chem Int Ed Engl 56:10717-10720
Tang, Rui; Habimana-Griffin, LeMoyne M; Lane, Daniel D et al. (2017) Nanophotosensitive drugs for light-based cancer therapy: what does the future hold? Nanomedicine (Lond) 12:1101-1105
Miller, Jessica P; Maji, Dolonchampa; Lam, Jesse et al. (2017) Noninvasive depth estimation using tissue optical properties and a dual-wavelength fluorescent molecular probe in vivo. Biomed Opt Express 8:3095-3109

Showing the most recent 10 out of 273 publications